CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
CPXX was delisted on the 11th of July, 2016.
7 hedge funds and large institutions have $10.8M invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
4% more capital invested
Capital invested by funds: $10.4M → $10.8M (+$390K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$643K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$50.8K |
| 3 |
CPA
Cowen Prime Advisors
New York
|
+$43.1K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$9.76K |
| 5 |
Morgan Stanley
New York
|
+$149 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$181K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
1
Caxton Corporation
Princeton,
New Jersey
| $7.12M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.02M | -$181K | -53,515 | -8% |
|
|
OM
3
Opaleye Management
Boston,
Massachusetts
| $1.03M | +$50.8K | +15,000 | +5% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $614K | +$643K | +189,967 | New |
|
|
CPA
5
Cowen Prime Advisors
New York
| $40K | +$43.1K | +12,750 | New |
|
|
U
6
UBS
Zurich,
Switzerland
| $10K | +$9.76K | +2,885 | +1,803% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$2K | -540 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$2K | -467 | Closed |
|
|
9
Morgan Stanley
New York
| – | +$149 | +44 | New |
|
CPXX Hedge Fund Activity: Q1 2014 in Review
7 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q1 2014, worth a combined $10.8M — up 3.7% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CPXX positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $643K. The largest seller was Sabby Management, cutting an estimated $181K.
- 7 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q1 2014, up from 6 in Q4 2013.
- Funds reported $10.8M of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q1 2014, up 3.7% quarter-over-quarter.
- 3 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q1 2014 and 2 closed out, a net change of +1 holder.
- The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK buyer in Q1 2014 was Vanguard Group, an estimated $643K added.
- The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q1 2014 was Sabby Management, an estimated $181K sold.
Based on aggregated 13F filings for Q1 2014.